Back

Perspectives on results from recent CVOTs in type 2 diabetes.

26 August 2017 (16:10 - 16:20)
Organised by:
Congress Presentation Part of: Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists? Diabetes, dysglycaemia and metabolic syndrome Open Access ESC Congress 2017

About the speaker

Photo
Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.
Professor L. Ryden (Stockholm, SE)
Slides Video
Presentation thumbnail
Cardiovascular effects of GLP-1 receptor agonists.
Doctor J. Plutzky (Boston, US)
Slides Video
Presentation thumbnail
Results from the LEADER cardiovascular outcomes trial.
Professor N. Poulter (London, GB)
Slides Video
Presentation thumbnail
Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?
Professor L. Ryden (Stockholm, SE) Professor N. Poulter (London, GB) Doctor J. Plutzky (Boston, US)
Slides Video

Access the full session

Session thumbnail
Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

The Event

Event poster

ESC Congress 2017

26 August 2017 16:10 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources